Author(s):
Ganesh D. Barkade, Sakshi A. Bhongal, Pallavi K. Dani, Shrutika R. Gund
Email(s):
ganeshbarkade7@gmail.com
DOI:
10.52711/2231-5659.2022.00053 
Address:
Ganesh D. Barkade1, Sakshi A. Bhongal2, Pallavi K. Dani2, Shrutika R. Gund2
1Assistant Professor, Department of Pharmaceutical Chemistry, Dr. Vithalrao Vikhe Patil Foundations College of Pharmacy, Ahmednagar - 414111.
2Research Scholar, Dr. Vithalrao Vikhe Patil Foundations College of Pharmacy, Ahmednagar – 414111.
*Corresponding Author
Published In:
Volume - 12,
Issue - 4,
Year - 2022
ABSTRACT:
Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder in women. It generally occurs in the female of reproductive age. Polycystic ovary syndrome (PCOS) is also known as Stein Leventhal Syndrome. According to World Health Organization (WHO), PCOS impacted 116 million women worldwide. The purpose of this review is to summarize physiological characteristics of PCOS like obesity, hirsutism, infertility, acne, etc. that are common among women diagnosed with polycystic ovary syndrome. . This review also highlights a brief outline of signs and symptoms, pathophysiology, risk factors and treatment with drugs acting on anovulation, infertility, and symptoms of the polycystic ovarian syndrome.
Cite this article:
Ganesh D. Barkade, Sakshi A. Bhongal, Pallavi K. Dani, Shrutika R. Gund. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(4):309-3. doi: 10.52711/2231-5659.2022.00053
Cite(Electronic):
Ganesh D. Barkade, Sakshi A. Bhongal, Pallavi K. Dani, Shrutika R. Gund. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(4):309-3. doi: 10.52711/2231-5659.2022.00053 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2022-12-4-9
REFERENCES:
1. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. TherAdvReprod Health. 2020; 18; 14:2633494120911038. doi: 10.1177/2633494120911038.
2. Shermin S. Noor A. Jahan S. Polycystic Ovary Syndrome: A Brief Review with Recent Updates. Delta Medical College Journal. 2020; 7(2), 84–99. doi: 10.3329/dmcj.v7i2.45567
3. Du Q, Wang YJ, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin. 2012; 28(5):723–730.
4. Morang M, Chasta P and Chandrul M. A Review on “Polycystic Overy Syndrom PCOS”. International Journal of Trend in Scientific Research and Development. 2019; 3: 60-66. doi:10.31142/ijtsrd23542.
5. Strauss JF. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci. 2003; 997: 42–48.
6. Lin LH, Baracat MC, Gustavo AR, et al. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynaecol Obstet. 2013; 120:115–118.
7. Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyper-androgenic syndrome. An Androgen Excess Society guideline. J Clin Edocrinol Metab. 2006; 91: 4237–4245.
8. Malik S, Jain K, Talwar P, Prasad S, Dhorepatil B, Devi G, Khurana A, Bhatia V, Chandiok N, Kriplani A, Shah D, Sinha G, Unni J. et al. Management of Polycystic Ovary Syndrome in India. FertilSci Res 2014; 1: 23-43.
9. Polak, Kinga, Czyzyk, A, Simoncini, Tommaso, Meczekalski, B. New markers of insulin resistance in polycystic ovary syndrome: Journal of Endocrinological Investigation. 2016; 40. 10.1007/s40618-016-0523-8.
10. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009; 2(4):232-239.
11. Andrade VH, Mata AM, Borges RS, Costa-Silva DR, Martins LM, Ferreira PM, Cunha-Nunes LC, Silva BB. Current aspects of polycystic ovary syndrome: A literature review. Rev Assoc Med Bras (1992). 2016; 62(9):867-871. doi: 10.1590/1806-9282.62.09.867.
12. Sam S, Ehrmann DA. Pathogenesis and Consequences of Disordered Sleep in PCOS. Clin Med Insights Reprod Health. 2019; 3; 13:1179558119871269. doi: 10.1177/1179558119871269.
13. Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment with Emphasis on Adolescent Girls. J Endocr Soc. 2019; 14; 3(8):1545-1573. doi: 10.1210/js.2019-00078.
14. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5):487-525. doi: 10.1210/er.2015-1018.
15. Naderpoor N, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ. Obesity and polycystic ovary syndrome. Minerva Endocrinol. 2015; 40(1):37-51.
16. Baldani DP, Skrgatic L, Ougouag R. Polycystic Ovary Syndrome: Important UnderrecognisedCardiometabolic Risk Factor in Reproductive-Age Women. Int J Endocrinol. 2015;2015: 786362. doi: 10.1155/2015/786362.
17. Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clin Med Res. 2004; 2(1):13-27. doi: 10.3121/cmr.2.1.13.
18. Ali AT. Polycystic ovary syndrome and metabolic syndrome. CeskaGynekol. 2015; 80(4):279-89.
19. Christopher R. McCartney, M.D. and John C. Marshall, M.B., Ch.B., M.D. Polycystic Ovary Syndrome N Engl J Med. 2016; 07; 375(1): 54–64. doi:10.1056/NEJMcp1514916
20. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Rev Obstet Gynecol. 2011; 4(2):45-51.
21. Colleen B, and Robert LR. Polycystic Ovary Syndrome in Adolescence EndocrinolMetabClin North Am. 2005; 34(3): 677–x. doi:10.1016/j.ecl.2005.04.005.
22. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011; 8 (3):25-35. doi: 10.2147/IJWH.S11304.
23. Geller DH, Pacaud D, Gordon CM, Misra M; of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). Int J PediatrEndocrinol. 2011 Aug 26; 2011(1):9. doi: 10.1186/1687-9856-2011-9.
24. Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013; 38(6):336-55.
25. Aubuchon M, Legro RS. Polycystic ovary syndrome: Current infertility management. Clin Obstet Gynecol. 2011; 54(4):675–684.
26. Christakou C, Diamanti-Kandarakis E. Polycystic ovary syndrome--phenotypes and diagnosis. Scand J Clin Lab Invest Suppl. 2014; 244:18-22. doi: 10.3109/00365513.2014.936675.
27. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol. 2006, 154(6):763-75. doi: 10.1530/eje.1.02156.
28. McFarland C. Treating polycystic ovary syndrome and infertility. MCN Am J Matern Child Nurs. 2012; 37(2):116–121.
29. Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. FertilSteril. 2010, 94(5):1565-74. doi: 10.1016/j.fertnstert.2010.03.081.
30. Lee TT, Rausch ME. Polycystic ovarian syndrome: Role of imaging in diagnosis. Radiographics. 2012; 32(6):1643–1657.